1. Home
  2. ARMK vs PRAX Comparison

ARMK vs PRAX Comparison

Compare ARMK & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aramark

ARMK

Aramark

HOLD

Current Price

$39.98

Market Cap

10.1B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$293.73

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARMK
PRAX
Founded
1959
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1B
9.6B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
ARMK
PRAX
Price
$39.98
$293.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
15
Target Price
$47.14
$572.13
AVG Volume (30 Days)
2.3M
321.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.20%
N/A
EPS Growth
23.23
N/A
EPS
0.36
N/A
Revenue
$18,506,299,000.00
N/A
Revenue This Year
$8.97
N/A
Revenue Next Year
$6.13
$6,395.88
P/E Ratio
$110.99
N/A
Revenue Growth
6.35
N/A
52 Week Low
$29.92
$26.70
52 Week High
$44.49
$354.87

Technical Indicators

Market Signals
Indicator
ARMK
PRAX
Relative Strength Index (RSI) 53.05 37.08
Support Level $37.88 $290.36
Resistance Level $40.64 $322.32
Average True Range (ATR) 0.96 17.42
MACD -0.18 -5.25
Stochastic Oscillator 50.00 7.97

Price Performance

Historical Comparison
ARMK
PRAX

About ARMK Aramark

Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients, including schools, healthcare facilities, and entertainment venues.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: